Join the club for FREE to access the whole archive and other member benefits.

BBC reports on two different uses of AI in pharmaceutical healthcare


Key points from article :

Israeli health-tech firm Genetika+ uses artificial intelligence (AI) software to best match antidepressants to patients, by testing them on brain cells grown from stem cells from a patient's blood sample.

"We are in the right time to be able to marry the latest computer technology and biological technology advances," says Dr Cohen Solal, Genetika+ co-founder.

Dr Heba Sailem, senior lecturer at King's College London,  says that the potential for AI to transform the global pharmaceutical industry is huge.

"... senior people [in pharmaceutical companies] got to where they are by doing things the old way," explained author Calum Chace.

Alex Zhavoronkov, co-founder of Insilico Medicine, says its AI platform has reduced the time to identify potential drugs from four years to "under 18 months, for a fraction of the cost".

Genetika+ tests drugs against a patient's own cells; Insilico Medicine is slashing the time taken for drug discovery

Mentioned in this article:

Click on resource name for more details.

Alex Zhavoronkov

CEO of InSilico Medicine & Deep Longevity. CSO of Biogerontology Research Foundation

Calum Chace

Global keynote speaker about artificial intelligence and related technologies


Personalizing depression treatment for every individual suffering from depression to help them recover faster and better

Heba Sailem

Senior Lecturer in Biomedical AI and Data Science at King's College London

Insilico Medicine

Biotechnology company that uses artificial intelligence to develop new drugs and for aging research

Talia Cohen Solal

CEO and Co-founder at Genetika+

BBC reports on two different uses of AI in pharmaceutical healthcare